Cogent Biosciences Inc's Customers Performance

Name: Cogent Biosciences Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

COGT

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


COGT's Source of Revenues		• List of COGT Customers

for the same period Cogent Biosciences Inc

• List of COGT Customers

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Cogent Biosciences Inc's Comment on Sales, Marketing and Customers

News about Cogent Biosciences Inc Contracts

Cogent Biosciences Surpasses Enrollment Targets and Advances in GIST Phase 3 PEAK Trial Amidst Financial Challenges...

Breaking New Ground in GIST Therapy: Cogent Biosciences Phase 3 PEAK Trial Completes Enrollment and Surpasses Interim Futility AnalysisIn a significant milestone for the fight against Gastrointestinal Stromal Tumors (GIST), Cogent Biosciences has announced that its Phase 3 PEAK trial has successfully completed enrollment and moved beyond the interim futility analysis. This crucial step not only underscores the progress in GIST research but also raises hopes for improved therapeutic options for patients battling this complex cancer. Overachieving Enrollment Targets: A New Hope for GIST PatientsCogent Biosciences set a high bar when they launched the PEAK Phase 3 trial, targeting ample patient involvement to...

Bezuclastinib Shows Promising Results in the Treatment of NonAdvanced Systemic Mastocytosis

In their recent announcement, Cogent Biosciences revealed additional clinical data from Part 1 of the SUMMIT trial, showcasing the potential of bezuclastinib in patients with NonAdvanced Systemic Mastocytosis (NonAdvSM). The trial evaluated the efficacy and safety of this promising drug, and the results have generated significant excitement within the medical community.Key Findings:Patients who were treated with a dosage of 100 mg bezuclastinib demonstrated remarkable improvements in their most severe symptoms and mast cell reactions. This breakthrough in managing the debilitating symptoms associated with NonAdvSM offers hope to patients who previously had limited treatment options. The reduction in symptoms...

Cogent Biosciences' Bezuclastinib Elicits Promising Results in Rare Mastocytosis Trial, Initiates Next Phase for Approval

Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic MastocytosisCogent Biosciences, a leading biotechnology company specializing in the development of innovative therapies for rare genetic disorders, recently released positive data from Part 1b of their SUMMIT clinical trial. The trial evaluated the efficacy and safety of Bezuclastinib in patients with Nonadvanced Systemic Mastocytosis (nSM). This exciting news marks a significant milestone in the quest to find effective treatments for this rare and debilitating condition.Systemic Mastocytosis is a rare disorder characterized by an excessive accumulation of mast cells in various ...

Cogent Biosciences Sets Path for Precision Therapies Advancements in 2024 and Beyond

Cogent Biosciences Announces Exciting Milestones for 2024 in Precision Therapies DevelopmentWALTHAM, Mass. and BOULDER, Colo., Jan. 09, 2024 - Cogent Biosciences, Inc. (Nasdaq: COGT), a leading biotechnology company specializing in the development of precision therapies for genetically defined diseases, is set to embark on a series of key milestones in 2024. The company unveiled its plans ahead of its participation in J.P. Morgan s 42nd annual healthcare conference.Cogent Biosciences has gained significant recognition in the field of biotechnology and precision medicine. With its focus on genetically defined diseases, the company offers a novel approach to developing targeted therapeutics that could potentia...

COGT's Stock Performance relative to it's Customers

COGT's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Cogent Biosciences Inc	5,827.87	7.87	-354.30	258
SUBTOTAL	0.00	0.00	0.00	-

Sources: Cogent Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Cogent Biosciences Inc’s corporate clients.
For your research, we’ve provided 9 tables on Cogent Biosciences Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.